<DOC>
	<DOCNO>NCT01299610</DOCNO>
	<brief_summary>This study randomise , double-blind , placebo-controlled study ass efficacy GW870086X cream formulation subject moderate severe atopic dermatitis . Subjects assign take 3 4 possible treatment 21 ±2 day : GW870086X 0.2 % cream , GW870086X 2 % cream , FP 0.05 % cream ( positive control ) placebo cream . All subject randomise receive placebo cream . Three index lesion locate arm and/or leg ( one ) identify per subject treatment apply lesion .</brief_summary>
	<brief_title>A Study Test Effect 2 Different Doses Topical GW870086X Atopic Dermatitis Also Including Postive Control Placebo</brief_title>
	<detailed_description>This study randomise , double-blind , placebo-controlled study ass efficacy GW870086X cream formulation subject moderate severe atopic dermatitis . The primary objective study assess 3 lesion use Three Item Severity ( TIS ) score . The secondary objective assess safety tolerability GW870086X , assess individual lesion use Investigators Global Assessment ( IGA ) ass pharmacokinetics 21 day dose GW870086X administer cream . Twenty-five ( 25 ) subject atopic dermatitis randomise receive placebo 2 follow treatment : GW870086X 0.2 % , GW870086X 2 % , FP 0.05 % placebo . All subject receive placebo . Subjects apply 3 treatment daily 21 day treatment period . Three index lesion locate arm and/or leg ( one ) identify per subject treatment apply lesion throughout 21±2 day treatment period . Each index lesion represent common lesion patient i.e . least severe lesion .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Subjects diagnosis atopic dermatitis otherwise healthy . Male female 18 65 year age inclusive . A female subject eligible participate : • Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one protocol contraception method wish continue HRT study . Male subject female partner childbearing potential must agree use one protocol contraception method . BMI within range 19.0 29.0 kg/m2 ( inclusive ) . Subjects must body surface area ( BSA ) disease involvement &gt; 5 % assessed rule nine method . Patients must willing refrain current active therapy least 10 day prior dose , Capable give write informed consent . Single QTc , QTcB &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . The subject present systemic disorder , active skin disease subject present scar , mole , tattoo , body piercings , sunburn test area could interfere assessment lesion screen . The subject atopic dermatitis restrict face , foot hand . The subject current complication atopic dermatitis treatment antiinfectives indicate . History recent ( &lt; 6 month ) active presence current superficial skin infection viral aetiology The subject diagnose contact dermatitis area target lesion , seborrheic dermatitis and/or occupational eczema predilection sit atopic dermatitis . The subject topical transdermal treatment near intend site application within 14 day prior first application study medication . The subject systemic treatment atopic dermatitis within 28 day first dose study medication . Foreseeable intensive UV exposure study . Subjects must expose direct sunlight skin tan device duration study . The subject use topical treatment tar corticosteroid within 14 day first dose study medication except topical 1 % hydrocortisone may use twice daily patient severe disease require stepdown therapy washout period 3 day prior study start , hydrocortisone must discontinue . The subject use topical treatment buproprion within 14 day first dose study medication . History cutaneous photodisorder . History allergy steroid component test medication . History presence skin ( atopic dermatitis ) , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . Subjects history diaphoresis/excessive sweating restrict palms face . A positive test Hepatitis B Hepatitis C antibody . Current chronic history liver disease , know hepatic biliary abnormality . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Consumption red wine , Seville oranges , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>GW870086X</keyword>
	<keyword>TIS</keyword>
	<keyword>IGA</keyword>
</DOC>